

**DAUNORUBICIN KINETICS AND DRUG  
RESISTANCE IN LEUKAEMIA**

**By  
Peter Galettis  
B. Sc. (Hons)**

**A thesis submitted in fulfillment of the requirements for the degree of  
Doctor of Philosophy in Science of the University of Technology, Sydney**

**March, 1996**

# Acknowledgements

I acknowledge receipt of an NSW State Health Department Scholarship that enabled the studies described in this thesis to be undertaken.

I wish to express my thanks to my supervisors Dr David Ma, Dr John Boutagy and Dr Anita Piper for their guidance and support.

I am especially grateful to Brownyn Williams and Dr John Marwood for their assistance in the preparation of this thesis.

I would like to thank Janet McLachlan for her help in performing the P glycoprotein assays.

I thank all the staff of Wards 12D and 12H Royal North Shore Hospital for their assistance in obtaining patient blood samples.

I would also like to thank the entire staff of both the Haematology and Clinical Pharmacology Departments at Royal North Shore Hospital for their help and support throughout my years of study.

Finally, I express my gratitude to John Burnside and Brownyn Williams for their moral support through all the good and bad times during my years at Royal North Shore Hospital.

## Abstract

The aims of this thesis were to examine: (1) plasma and cellular pharmacokinetics of daunorubicin and its major metabolite daunorubicinol in patients with acute leukaemia, and the relationships between pharmacokinetics, patient response and the presence of P glycoprotein; (2) actions of the multidrug resistance reversing agents cyclosporin A and trifluoperazine, at clinically achievable concentrations, on daunorubicin accumulation and retention in human leukaemia cell lines and patients with acute leukaemia; and (3) effect of daunorubicin on the cell membrane of both sensitive and resistant cell lines, with and without the multidrug resistance reversing agents.

Twenty-seven patients with acute leukaemia received daunorubicin as part of induction therapy. The plasma and cellular levels of daunorubicin and its metabolite daunorubicinol were determined using HPLC. There were no significant differences between patients who went into complete remission (12/23) compared to those who did not respond for any of the plasma pharmacokinetic parameters. There was a significant difference in the cellular daunorubicin and daunorubicinol area under the concentration-time curve between responders and non responders ( $p < 0.02$ ), as well as in cellular  $C_{max}$ , cellular clearance and cellular volume of distribution. Eleven patients were P glycoprotein positive and 10 P glycoprotein negative (no sample available for 2 patients). There was no correlation between patient response and the presence of P glycoprotein; nor a correlation between the cellular concentration of daunorubicin or daunorubicinol and P glycoprotein. Patients responding to chemotherapy had higher cellular daunorubicin and daunorubicinol compared to non responders. In contrast to *in vitro* studies, overexpression of P glycoprotein was not the reason for the lower cellular daunorubicin levels.

Cyclosporin A was capable of increasing both cellular accumulation and retention in the drug resistant CEM/VLB and HL 60/ADR cell lines, but not in the drug sensitive CEM and HL 60 cell lines. Trifluoperazine had no effect in any of the four cell lines. In contrast to the cell line findings, only the combination of cyclosporin A and trifluoperazine were able to increase both accumulation and retention in the blast cells of patients at initial presentation. The multidrug resistant reversing agents alone had no effect in increasing accumulation or retention in the blast cells of P glycoprotein positive patients, nor patients in relapse. The cell line studies show that at clinically relevant concentrations only cyclosporin A is capable of increasing daunorubicin accumulation in both the drug resistant P glycoprotein positive (VLB) and P glycoprotein negative (ADR) cell lines. Thus, cyclosporin A does not work only by inhibiting the actions of P glycoprotein. Trifluoperazine

was unable to reverse drug resistance at clinically relevant concentrations in either cell lines or patient blast cells. However, the combination of cyclosporin A and trifluoperazine increased accumulation in patient blast cells at initial presentation, suggesting that these agents may be more useful in patients at initial presentation than relapse.

Daunorubicin was immobilised by linking it to poly vinyl alcohol and the effect of immobilised-daunorubicin was studied on the four cell lines above. The immobilised-daunorubicin was able to decrease cell growth in the drug sensitive HL 60 cell line but not in the drug resistant VLB or ADR cell lines. Poly vinyl alcohol itself was cytotoxic to the CEM cell line. The multidrug resistance reversing agents cyclosporin A and trifluoperazine were only capable of increasing cytotoxicity in the HL 60 cell line, with no effect in the drug resistant VLB or ADR cell lines.

## Publications supporting this thesis

1. P. Galettis, J. Boutagy and D.D.F. Ma. (1994) Daunorubicin pharmacokinetics and the correlation with p-glycoprotein and treatment response in patients with acute leukaemia. *Br. J. Cancer* **70**, 324 - 329

## Publications in preparation

1. P. Galettis, J. Boutagy and D.D.F. Ma. (1996) Effects of the MDR reversing agents, cyclosporin A and trifluoperazine, on daunorubicin accumulation and retention in patient leukaemic cells.

In addition, some of the work contained in this thesis has been presented at Scientific Meetings as follows:


1. P. Galettis, D.D.F. Ma and J. Boutagy. (1990) Pharmacokinetics of daunorubicin and correlation with treatment outcome in acute leukaemia. Annual Scientific Meeting of the Haematology Society of Australia, Christchurch.
2. P. Galettis, D.D.F. Ma and J. Boutagy. (1990) Accumulation and retention of daunorubicin in the blasts from patients with leukaemia. Annual Scientific Meeting of the Haematology Society of Australia, Christchurch.
3. P. Galettis, D.D.F. Ma and J. Boutagy. (1991) Pharmacokinetics of daunorubicin and correlation with treatment outcome in acute leukaemia. AACR Special Conference in Cancer Research. Membrane Transport in Multidrug Resistance, Development and Disease, Banff.
4. D.D.F. Ma, P. Galettis, J. McLachlan and J. Boutagy. (1991) Clinical significance of in-vitro daunorubicin accumulation and retention in human leukaemias. VII Congress, Asian-Pacific Division, International Society of Haematology.
5. P. Galettis, J. Boutagy and D.D.F. Ma. (1992) Effects of MDR reversing agents

on cell lines and patient leukaemic cells. Vth World Conference on Clinical Pharmacology and Therapeutics, Yokohama.

6. J. Boutagy, P. Galettis and D.D.F. Ma. (1992) Relationship between treatment outcome, p-glycoprotein and daunorubicin pharmacokinetics. Vth World Conference on Clinical Pharmacology and Therapeutics, Yokohama.
7. P. Galettis, J. Boutagy and D.D.F. Ma. (1992) Effects of MDR reversing agents on cell lines and patient leukaemic cells. Annual Scientific Meeting of the Australasian Society of Clinical and Experimental Pharmacology and Toxicology, Sydney.
8. P. Galettis, J. Boutagy and D.D.F. Ma. (1993) Reversal of drug resistance by cyclosporin A via a non p-glycoprotein mechanism. Annual Scientific Meeting of the Australasian Society of Clinical and Experimental Pharmacology and Toxicology, Brisbane.

## **Preface**

The work described in this thesis was carried out in the Departments of Haematology and Clinical Pharmacology, Royal North Shore Hospital, under the supervision of Dr David Ma, Dr John Boutagy and Dr Anita Piper. This thesis has not been submitted for a degree at any other university. Full acknowledgement has been made where the work of others has been cited and used. A list of publications in support of this thesis is included.

A handwritten signature in black ink, appearing to read 'Peter Galettis', with a long horizontal line extending to the right.

**Peter Galettis**

# Table of Contents

Table of Contents .....	i
List of Figures .....	vi
List of Tables .....	viii
Glossary of Abbreviations .....	xi
<b>CHAPTER 1 .....</b>	<b>1</b>
<b>INTRODUCTION .....</b>	<b>1</b>
1.1. Mechanisms of Action of Anthracyclines .....	2
1.1.1. DNA Intercalation .....	2
1.1.2. Free Radical Formation .....	7
1.1.3. Cell Membrane Effects .....	10
1.2. Multidrug Resistance .....	14
1.2.1. P-glycoprotein Mediated Resistance .....	15
1.2.2. Reversal of Multidrug Resistance .....	17
1.2.3. Non P-glycoprotein Mediated Resistance .....	19
1.3. Acute Leukaemia .....	20
1.3.1. Treatment .....	21
1.3.2. Problems Associated with Treatment .....	24
1.3.3. Pgp and Acute Leukaemia .....	25
1.4. Pharmacokinetics .....	27
1.4.1. Principles .....	27
1.4.2. Pharmacokinetics of Anthracyclines .....	29
1.4.3. Metabolism of Anthracyclines .....	30
1.5. Aims of this Thesis .....	31
<b>CHAPTER 2 .....</b>	<b>33</b>
<b>Materials and Methods .....</b>	<b>33</b>
2.1. Materials .....	33



2.1.1. Cell Culture .....	33
2.1.2. HPLC Assay .....	34
2.1.3. P glycoprotein assay .....	34
2.1.4. Immobilisation .....	35
2.1.5. Cell Lines .....	35
2.1.6. Patients .....	35
2.2. Methods .....	36
2.2.1. Buffers .....	36
2.2.2. Culturing of Cells .....	36
2.2.3. Cell Viability .....	37
2.2.4. MTT assay .....	37
2.2.5. Clonogenic Assay .....	40
2.2.6. Collection of blood and sample preparations for pharmacokinetics ..	41
2.2.7. Accumulation/ Retention Experiments .....	41
2.2.7.1. Isolation of Cells .....	41
2.2.7.2. Accumulation .....	41
2.2.7.3. Retention .....	42
2.2.7.4. Retention with the addition of MDR reversing agents .....	42
2.2.8. HPLC assay .....	43
2.2.8.1. Chromatographic Conditions .....	43
2.2.8.2. Standard Solutions for Assay Calibration .....	43
2.2.8.3. Plasma Samples .....	43
2.2.8.4. Cellular Samples .....	45
2.2.9. Calculation of Pharmacokinetic Parameters .....	45
2.2.10. P glycoprotein assay .....	45
2.2.11. Immobilisation of DNR .....	46
2.2.11.1. Preparation of immobilised DNR .....	46
2.2.11.2. Washing of immobilised DNR .....	48
2.2.11.3. Amount of DNR bound to PVA .....	48
2.2.11.4. Sterilization of immobilised-DNR .....	49
2.2.11.5. Experiments using immobilised DNR .....	49

2.2.12. Statistics .....	49
<b>CHAPTER 3 .....</b>	<b>51</b>
<b>Actions of DNR and MDR Reversing Agents on Leukaemic Cell lines</b>	<b>51</b>
3.1. Introduction .....	51
3.2. Cytotoxicity of DNR on Cell lines .....	52
3.3. Effects of MDR reversing agents on DNR cytotoxicity .....	52
3.4. Cytotoxicity of DOL on Cell lines .....	59
3.5. Accumulation of DNR in Cell lines with or without MDR reversing agents.	59
3.5.1. CEM .....	60
3.5.2. VLB .....	60
3.5.3. HL 60 .....	60
3.5.4. ADR .....	65
3.6. Retention of DNR in Cell lines with or without MDR reversing agents.....	65
3.6.1. CEM .....	65
3.6.2. VLB .....	69
3.6.3. HL 60 .....	69
3.6.4. ADR .....	69
3.7. Effect of MDR reversing agents after removal of DNR .....	73
3.8. Accumulation and Retention of DOL by CEM .....	73
3.9. Discussion .....	73
<b>CHAPTER 4 .....</b>	<b>79</b>
<b>Pharmacokinetics of DNR in patients and the role of P glycoprotein..</b>	<b>79</b>
4.1. Introduction .....	79
4.2. Patients .....	80
4.3. Patients Response to Treatment .....	80
4.4. Pharmacokinetics .....	82
4.4.1. Plasma .....	82

4.4.2. Cellular .....	89
4.5. Relationships between Pharmacokinetics and Patient Response .....	91
4.5.1. Plasma Pharmacokinetics .....	96
4.5.2. Cellular Pharmacokinetics .....	96
4.6. P glycoprotein .....	100
4.7. Relationship between P glycoprotein and Patient Response .....	103
4.8. Relationship between P glycoprotein and Cellular Pharmacokinetics. ....	103
4.9. Discussion .....	105
 <b>CHAPTER 5 .....</b>	 <b>109</b>
<b>Effects of the MDR reversing agents Cy A and Tri on DNR</b>	
<b>accumulation and retention in patient leukaemic cells .....</b>	<b>109</b>
5.1. Introduction .....	109
5.2. Patients .....	110
5.3. Accumulation of DNR in acute leukaemic patients and the effect of the MDR Reversing agents .....	110
5.3.1. Presentation .....	110
5.3.1.1. Initial Presentation .....	110
5.3.1.2. Relapse .....	114
5.3.2. P glycoprotein .....	114
5.3.2.1. Pgp positive .....	114
5.3.2.2. Pgp negative .....	117
5.4. Retention of DNR in acute leukaemic patients and the effect of the MDR reversing agents .....	117
5.4.1. Presentation .....	117
5.4.1.1. Initial Presentation .....	117
5.4.1.2. Relapse .....	120
5.4.2. P glycoprotein .....	120
5.4.2.1. Pgp positive .....	120
5.4.2.2. Pgp negative .....	120

5.5. Relationship between patient presentation and Pgp .....	122
5.6. Discussion .....	122
<b>CHAPTER 6 .....</b>	<b>125</b>
<b>Actions of Immobilised-DNR .....</b>	<b>125</b>
6.1. Introduction .....	125
6.2. Preparation of immobilised-DNR .....	126
6.3. Amount of DNR bound to PVA .....	128
6.4. Amount of DNR released in immobilised-DNR experiments .....	128
6.5. Cytotoxicity of immobilised-DNR .....	128
6.6. Effects of MDR reversing agents .....	132
6.7. Discussion .....	139
<b>Chapter 7 .....</b>	<b>145</b>
<b>General Discussion .....</b>	<b>145</b>
7.1. Overview of the studies conducted .....	145
7.2. Implications and future work .....	152
<b>Bibliography .....</b>	<b>157</b>

## List of Figures

Figure 1.1	Structure of Anthracyclines	3
Figure 1.2	Diagram of DNR intercalated into d(CpGpTpApCpGp), showing intermolecular attractions	5
Figure 1.3	View of the intercalator perpendicular to the base plane	5
Figure 1.4	Free radical and alkylating intermediates produced by the anthracyclines	8
Figure 1.5	Free radical production from the DOX-iron complex	9
Figure 1.6	A diagrammatic representation of the proposed orientation of P-glycoprotein in the plasma membrane	16
Figure 2.1	Chromatograms obtained from patient plasma samples	44
Figure 2.2	Preparation of Immobilised-DNR	47
Figure 3.1	Dose response curve for the cytotoxic actions of DNR on the drug sensitive CEM cell line and drug resistant Pgp positive VLB cell line	53
Figure 3.2	Dose response curve for the cytotoxic actions of DNR on the drug sensitive HL 60 cell line and drug resistant Pgp negative ADR cell line	55
Figure 3.3	Dose response curve for the cytotoxic actions of DNR on the drug sensitive CEM cell line and the drug resistant Pgp positive VLB cell line	57
Figure 3.4	Dose response curve for the cytotoxic actions of DNR on the drug sensitive HL 60 cell line and the drug resistant Pgp negative ADR cell line	58
Figure 3.5	Concentration-time curve of DNR accumulation in the drug sensitive CEM cell line	61
Figure 3.6	Concentration-time curve of DNR accumulation in the drug	

	sensitive CEM cell line, drug resistant Pgp positive VLB cell line and the addition of Cy A to the VLB cell line	63
Figure 3.7	Concentration-time curve of DNR accumulation in the drug sensitive HL 60 cell line	64
Figure 3.8	Concentration-time curve of DNR accumulation in the drug sensitive HL 60 cell line, drug resistant Pgp negative ADR cell line and the addition of Cy A to the ADR cell line	66
Figure 3.9	Concentration-time curve of DNR retention in the drug sensitive CEM cell line	67
Figure 3.10	Concentration-time curve of DNR retention in the drug sensitive CEM cell line, drug resistant Pgp positive VLB cell line and the addition of Cy A to the VLB cell line	70
Figure 3.11	Concentration-time curve of DNR retention in the drug sensitive HL 60 cell line	71
Figure 3.12	Concentration-time curve of DNR retention in the drug sensitive HL 60 cell line, drug resistant Pgp negative ADR cell line and the addition of Cy A to the ADR cell line	72
Figure 3.13	The effect of leaving the MDR reversing agent after the removal of DNR	74
Figure 4.1	Plasma concentration-time curve for DNR and its metabolite DOL for all patients receiving a 50 mg/m <sup>2</sup> dose of DNR	83
Figure 4.2	Plasma concentration-time curve for DNR and its metabolite DOL for all patients receiving a 25 mg/m <sup>2</sup> dose of DNR	84
Figure 4.3	Cellular concentration-time curve for DNR and its metabolite DOL for all patients receiving a 50 mg/m <sup>2</sup> dose of DNR	90
Figure 5.1	Representative concentration-time curve of DNR accumulation in a patient (Patient 3) at initial presentation	112
Figure 5.2	Representative concentration-time curve of DNR retention in a patient (Patient 11) at initial presentation	118

## List of Tables

Table 1.1	Classification of Acute Leukaemia	22
Table 2.1	Concentrations of DNR in the MTT assays	38
Table 2.2	Concentrations of DNR in the MTT assays with modifiers	39
Table 3.1	IC 50 values for DNR with or without the MDR reversing agents in the CEM and VLB cell lines	54
Table 3.2	IC 50 values for DNR with or without the MDR reversing agents in the HL 60 and ADR cell lines	56
Table 3.3	Accumulation of DNR by Leukaemic Cell Lines	62
Table 3.4	Retention of DNR by Leukaemic Cell Lines	68
Table 4.1	Patient Characteristics	81
Table 4.2	Plasma DNR Pharmacokinetic Parameters	85
Table 4.3	Plasma DOL Pharmacokinetic Parameters	86
Table 4.4	Plasma DNR Pharmacokinetic Parameters adjusted for administered dose of DNR	87
Table 4.5	Plasma DOL Pharmacokinetic Parameters adjusted for administered dose of DNR	88
Table 4.6	Cellular DNR Pharmacokinetic Parameters	92
Table 4.7	Cellular DNR Pharmacokinetic Parameters adjusted for administered dose of DNR	93
Table 4.8	Cellular DOL Pharmacokinetic Parameters	94
Table 4.9	Cellular DOL Pharmacokinetic Parameters adjusted for administered dose of DNR	95

Table 4.10	Relationship between the plasma DNR pharmacokinetic parameters and patient response	97
Table 4.11	Relationship between the plasma DOL pharmacokinetic parameters and patient response	98
Table 4.12	Relationship between the cellular DNR pharmacokinetic parameters and patient response	99
Table 4.13	Relationship between the cellular DOL pharmacokinetic parameters and patient response	101
Table 4.14	Pgp measurements for patients in the pharmacokinetic study	102
Table 4.15	Relationship between P-glycoprotein and intracellular DNR or DOL	104
Table 5.1	Patient Characteristics	111
Table 5.2	Accumulation of DNR in the blast cells of patients with acute leukaemia at initial presentation and at relapse	113
Table 5.3	Detection of Pgp in patient blast cells	115
Table 5.4	Accumulation of DNR in the blast cells of patients with acute leukaemia according to P glycoprotein	116
Table 5.5	Retention of DNR in the blast cells of patients with acute leukaemia at initial presentation and at relapse	119
Table 5.6	Retention of DNR in the blast cells of patients with acute leukaemia according to P glycoprotein	121
Table 6.1	The amount of DNR released and cytotoxicity of the media	127
Table 6.2	The effect of CL-PVA and immobilised-DNR on the drug sensitive CEM cell line and its drug resistant subline VLB	130
Table 6.3	The effect of CL-PVA and immobilised-DNR on the drug sensitive HL 60 cell line and its drug resistant subline ADR	131
Table 6.4	The effect of the MDR reversing agents Cy A and Tri on the CEM and VLB cell lines	133



Table 6.5	The effect of the MDR reversing agents Cy A and Tri on the CEM and VLB cell lines	134
Table 6.6	Effect of the MDR reversing agents on the cytotoxicity of immobilised-DNR in the drug sensitive CEM cell line	136
Table 6.7	Effect of the MDR reversing agents on the cytotoxicity of immobilised-DNR in the drug resistant VLB cell line	137
Table 6.8	Effect of the MDR reversing agents on the cytotoxicity of immobilised-DNR in the drug sensitive HL 60 cell line	138
Table 6.9	Effect of the MDR reversing agents on the cytotoxicity of immobilised-DNR in the drug resistant ADR cell line	140
Table 7.1	Cytotoxicity and accumulation of DNR in drug sensitive (CEM, HL 60) and drug resistant (VLB, ADR) cell lines with and without MDR reversing agents	147

## Glossary of Abbreviations

ACDA	acid citrate dextrose A
ADR	HL 60/ADR, doxorubicin resistant HL 60 subline
ALL	acute lymphocytic leukaemia
AML	acute myeloid leukaemia
ANLL	acute nonlymphocytic leukaemia
Ara C	cytosine arabinoside
at-MDR	atypical multidrug resistance
AUC	area under the curve
AUMC	area under the first moment curve
CEM	T cell lymphoblastic leukaemia cell line
CL	clearance
CL-PVA	cross linked polyvinyl alcohol
C <sub>max</sub>	maximum drug concentration
CR	complete remission
Cy A	cyclosporin A
DMSO	dimethyl sulphoxide
DNA	deoxyribonucleic acid
DNR	daunorubicin
DOL	daunorubicinol
DOX	doxorubicin
DSIM	double strength iscoves medium
EPI	epirubicin

FCS	foetal calf serum
FE	Fisher exact test
Fr	Friedman two-way analysis of variance
GSH	glutathione
HL 60	acute myeloid leukaemia cell line
HPLC	high performance liquid chromatography
IC 50	inhibitory dose at 50% cell death
IDA	idarubicin
Imm-DNR	immobilized-daunorubicin
KW	Kruskal-Wallis one way analysis of variance
MDR	multidrug resistance
mdr1	multidrug resistance gene
mRNA	messenger ribonucleic acid
MRP	multidrug resistance-associated protein
MRT	mean residence time
MTT	3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
MW	Mann-Whitney U test
n	number
NR	non responders
PBS	phosphate buffered saline
PCR	polymerase chain reaction
Pgp	P-glycoprotein
PKC	protein kinase C
PR	partial remission

PVA	polyvinyl alcohol
RNA	ribonucleic acid
SD	standard deviation
SOD	superoxide dismutase
T <sub>m</sub>	transition temperature
T <sub>max</sub>	time at maximum drug concentration
topo II	topoisomerase II
Tri	trifluoperazine
V <sub>d</sub>	volume of distribution
VLB	VLB 100, drug resistant CEM subline
W	Wilcoxon signed rank test